Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 320

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Endometrial cancer+2

Not recruiting

Study on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Selinexor
  • Sponsor:Karyopharm Therapeutics Inc.

Malignant melanoma

Not recruiting

Study Comparing High Dose Interferon, Ipilimumab, and Pembrolizumab for Patients with High Risk Resected Melanoma

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Cancer Trials Ireland

Peritoneal sarcoma+2

Not recruiting

Study of mirvetuximab soravtansine compared to standard chemotherapy in women with platinum-resistant advanced ovarian cancer with high folate receptor expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Immunogen Inc.

Colorectal cancer metastatic

Not recruiting

Study comparing trifluridine/tipiracil with bevacizumab versus capecitabine with bevacizumab as first-line treatment for patients with metastatic colorectal cancer who cannot receive intensive therapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effects of Durvalumab, Tremelimumab, and Bevacizumab in Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study of Tusamitamab Ravtansine with Pembrolizumab and Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Aveo Pharmaceuticals Inc.

Nasopharyngeal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Adults with Recurrent or Metastatic, Platinum-Resistant Nasopharyngeal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Fondazione GONO Plus

Basal cell carcinoma

Not recruiting

Study on Sonidegib for Patients with Locally Advanced Basal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonidegib
  • Sponsor:Fondazione GONO Plus

Metastases to central nervous system

Not recruiting

Study of SGM-101 fluorescent antibody to detect brain metastases from colorectal cancer during surgery

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leiden University Medical Center

Pancreatic carcinoma metastatic

Not recruiting

Study of Tumor Treating Fields with Atezolizumab, Gemcitabine, and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Novocure GmbH

Rectal cancer

Not recruiting

Study of SGM-101 Fluorescent Imaging for Detection of Early Rectal Cancer in Patients with Suspected T1 Adenocarcinoma or High-Grade Dysplasia

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leiden University Medical Center

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.